- Home
- FN vs MRNA Comparison
FN vs MRNA Comparison
Compare FN & MRNA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FN
- MRNA
- Stock Information
- Founded
- FN 1999
- MRNA 2010
- Country
- FN Cayman Islands
- MRNA United States
- Employees
- FN N/A
- MRNA N/A
- Industry
- FN Telecommunications Equipment
- MRNA Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- FN Utilities
- MRNA Health Care
- Exchange
- FN Nasdaq
- MRNA Nasdaq
- Market Cap
- FN 12.1B
- MRNA 9.8B
- IPO Year
- FN 2010
- MRNA 2018
- Fundamental
- Price
- FN $383.60
- MRNA $27.89
- Analyst Decision
- FN Buy
- MRNA Hold
- Analyst Count
- FN 7
- MRNA 17
- Target Price
- FN $317.17
- MRNA $42.40
- AVG Volume (30 Days)
- FN 522.1K
- MRNA 12.3M
- Earning Date
- FN 11-03-2025
- MRNA 11-06-2025
- Dividend Yield
- FN N/A
- MRNA N/A
- EPS Growth
- FN 13.21
- MRNA N/A
- EPS
- FN 9.17
- MRNA N/A
- Revenue
- FN $3,419,327,000.00
- MRNA $3,078,000,000.00
- Revenue This Year
- FN $20.32
- MRNA N/A
- Revenue Next Year
- FN $15.31
- MRNA $9.75
- P/E Ratio
- FN $41.81
- MRNA N/A
- Revenue Growth
- FN 18.60
- MRNA N/A
- 52 Week Low
- FN $148.55
- MRNA $23.15
- 52 Week High
- FN $397.26
- MRNA $59.73
- Technical
- Relative Strength Index (RSI)
- FN 57.09
- MRNA 58.77
- Support Level
- FN $358.28
- MRNA $26.91
- Resistance Level
- FN $380.38
- MRNA $28.99
- Average True Range (ATR)
- FN 12.94
- MRNA 1.22
- MACD
- FN -1.71
- MRNA 0.35
- Stochastic Oscillator
- FN 38.48
- MRNA 76.78
About FN Fabrinet
Fabrinet provides advanced optical packaging and precision optical, electro-mechanical, and electronic manufacturing services to original equipment manufacturers of complex products, such as optical communication components, modules and sub-systems, industrial lasers, automotive components, medical devices, and sensors. The company offers a broad range of advanced optical and electro-mechanical capabilities across the entire manufacturing process, including process design and engineering, supply chain management, manufacturing, complex printed circuit board assembly, advanced packaging, integration, final assembly, and testing. The company generates the majority of its revenue from North America and Asia-Pacific, with the rest from Europe.
About MRNA Moderna Inc.
Moderna is a commercial-stage biotech that was founded in 2010 and had its initial public offering in December 2018. The firm's mRNA technology was rapidly validated with its covid vaccine, which was authorized in the United States in December 2020. Moderna had 35 mRNA development candidates in clinical studies as of August 2025. Programs span a wide range of therapeutic areas, including infectious disease, oncology, cardiovascular disease, and rare genetic diseases.